Aurinia settles with Teva, helping stave off potential Lupkynis generic until late 2036

Aurinia Pharmaceuticals has struck a patent infringement settlement with Teva Pharmaceuticals, which should help stave off Teva's proposed generic for its lupus drug, Lupkynis (voclosporin), in the United States until December of 2036. With the deal, Aurinia's share price increased by 7%.